openPR Logo
Press release

The Generic Oncology Drugs Market to virtually grow beyond geographies

12-07-2021 01:05 PM CET | Health & Medicine

Press release from: Persistence Market Research

The Generic Oncology Drugs Market to virtually grow beyond

The Generic Oncology Drugs Market is all set to be in the driver’s seat shortly. Technology adoption once looked upon as a costly endeavor, is slated to witness a drastic transformation in the form of granular applications. Technologies like DevOps and AIOps are constructively disrupting the healthcare IT sector and are expected to create wonders in this regard in the upcoming period.

Sales revenue from generic oncology drugs in 2020 was US$ 23 Bn, which is expected to surge to US$ 41.5 Bn by the end of 2031. Analysts at Persistence Market Research have also predicted the market to rise at a healthy CAGR of 6% over the next ten years.

Instances of cancer cases have risen exponentially across the globe. From diagnosis to treatment, all aspects of the disease are being researched extensively by numerous market players. Oncology treatment and drugs have proven to be very expensive for everyone, and this has been affecting overall treatment of cancer globally.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.persistencemarketresearch.com/samples/25480

Research is focusing on developing new and cost-effective generic oncology drugs that would be helpful in treatment of types of cancers. A major trend to watch out for over the decade would be the use of nanotechnology in the development of generic oncology drugs. With cancer rates surging, the need for a diverse portfolio of generic drugs is being realized, and major as well as new market players are investing in developing a vast portfolio that caters to most needs of patients suffering from different cancer conditions.

Prime players in the industry are investing in the research & development of new products, which, in turn, is expanding their product portfolios across various cancer types.

In September 2021, MSN Labs, a pharmaceutical firm based in India, announced the launch of its new generic drug that will be used in treatment of renal cancer. The drug is called Cabolong, which is a branded generic of Cabozantinib. The drug will be available for treatment in three strength factors of 20mg, 40mg, and 60mg.
In February 2021, Glenmark Pharma, a renowned name in the pharmaceutical industry announced the launch of a new generic cancer drug for the treatment of kidney cancer. This drug is the generic version of FDA approved Suntinib and is named SUTIB.

Key Takeaways from Market Study

The global generic oncology drugs market is predicted to expand at a CAGR of 6% through 2031.
Generic oncology drugs revenue is anticipated to top US$ 41.5 Bn by the end of the decade.
The South Asia market is predicted to rise at the fastest CAGR over the decade.
In 2020, global market revenue totaled a net worth of US$ 23 Bn.
Increasing incidence of cancer across the globe, growing focus on healthcare, rising healthcare expenditure, and advancements in treatment technologies and drugs are some of the major factors influencing industry growth.

“Key players are focusing on diversifying their product portfolios in order to fulfil high demand for generic oncology drugs,” says a Persistence Market Research analyst.

For critical insights, request for methodology @ https://www.persistencemarketresearch.com/methodology/25480

Company Profiles:

Novartis AG
Pfizer Inc.
GlaxoSmithKline plc
CELGENE CORPORATION
Teva Pharmaceutical Industries Ltd.
Merck & Company, Inc
Aurobindo Pharma.
Hikma Pharmaceuticals PLC
Mylan N.V.
NATCO Pharma Limited.

Get a Customized Scope to Match Your Need Ask an Expert- sales@persistencemarketresearch.com

Competitive Landscape

The global market for generic oncology drugs has been identified as a fairly fragmented space due to the presence of a high number of market participants.

Some of the key market players included in the report are Novartis AG, Pfizer Inc., GlaxoSmithKline plc, CELGENE CORPORATION, Teva Pharmaceutical Industries Ltd., Merck & Company, Inc, Aurobindo Pharma., Hikma Pharmaceuticals PLC, Mylan N.V., and NATCO Pharma Limited.

These are identified as key manufacturers of generic oncology drugs. They are engaged in market expansion activities and the research & development of new oncology drugs.

More Valuable Insights on Offer

Persistence Market Research, a research and consulting firm, has published a new market research report on the global generic oncology drugs market that contains industry analysis of 2016–2020 and opportunity assessment for 2021–2031.

The report provides in-depth analysis of the market through different segments, namely, molecule type, by route of administration, by distribution channel, and region. The report also provides supply and demand trends along with an overview of the parent market.

For in-depth competitive analysis, buy now @ https://www.persistencemarketresearch.com/checkout/25480

Contact us:
305 Broadway, 7th Floor
New York City, NY 10007 United States
Ph.no. +1-646-568-7751
E-mail id- sales@persistencemarketresearch.com
Website: https://www.persistencemarketresearch.com

About us-
Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on “micros” by Persistence Market Research helps companies overcome their “macro” business challenges.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The Generic Oncology Drugs Market to virtually grow beyond geographies here

News-ID: 2488230 • Views: 156

More Releases from Persistence Market Research

Plantbased Protein Market to Witness Rise in Revenues During the Period 2019 - 2 …
Persistence Market Research has published a report on the plant-based protein market, which includes the global industry analysis for 2014-2018 and opportunity assessment for 2019-2029, and projects that the global plant-based protein market is expected to reach ~ US$ 9.6 Bn by the end of 2019 in terms of value, and is forecasted to reach ~ US$ 17.3 Bn by the end of 2029. According to the report, proteins are
The Chained Consumer Foodservice Market To Grasp Through The Fine Courses Of Nov …
The latest study by Persistence Market Research opines that the global chained consumer foodservice market is more popular than ever with paradigm changes in the way guests are eating and receiving their food. The chained consumer foodservice service market is expected to grow by around 4% over the forecast years, producing over US$ 280 Bn of incremental value from 2019 to 2027. This is partly driven by technology and mobile
New Product Launches To Put The Natural Organic Personal Care Product Market In …
The global natural and organic personal care products market was valued at ~US$ 10 Bn in 2014, which is estimated to reach ~US$ 14 Bn by the end of 2019. The natural and organic personal care products market is projected to expand at a robust CAGR during the next decade. Persistence Market Research (PMR) recently released a new market research on the natural and organic personal care products market covering
The Digestive Remedies Market To Ride On The Curve Of Innovation
According to a recently published PMR report, global digestive remedies market in 2018 exceeded US$ 15 Bn and is expected to grow at a moderate CAGR during the forecast period. Digestive remedies such as probiotics are used for therapy of gastrointestinal (GI) illnesses. The most prevalent digestive disorders include indigestion, heartburn, diarrhea, irritable bowel syndrome (IBS), movement disease, pediatric digestive illnesses, and constipation. To remain ‘ahead’ of your competitors, request

All 5 Releases


More Releases for Pharma

Global Deferasirox Market 2018 - Novartis, Cipla, Sun Pharma, Natco Pharma
Apex Market Reports, recently published a detailed market research study focused on the “Deferasirox Market” across the global, regional and country level. The report provides 360° analysis of “Deferasirox Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Deferasirox on the basis of
Big Pharma Outlook 2026
Boston, MA ReportsWorldwide has announced the addition of a new report title Big Pharma Outlook 2026 to its growing collection of premium market research reports. Pharmavitae Analytics casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals at a low single-digit compound annual growth rate (CAGR) of 0.9%. Using in-house sales forecasts,
Erythrocyte Catalase Market 2017 - Sanofi, Palam Pharma, Bioxera, Zafax Pharma
Apex Research, recently published a detailed market research study focused on the "Erythrocyte Catalase Market" across the global, regional and country level. The report provides 360° analysis of "Erythrocyte Catalase Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Erythrocyte Catalase industry, and estimates the future trend of Erythrocyte Catalase market on
12th World Pharma Congress
Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting in an abundant knowledge of the mechanisms driving drug discovery and development. Pharmaceutical Formulation Market size was USD $147billion in 2015 and is anticipated to reach around USD 175.1 billion by 2018. In USA, the total number of new drugs approved between
12th World Pharma Congress
Conference Series has taken an initiation to conduct International Pharma Congress worldwide. From several years Conference Series has been conducting Pharma Congress conferences in major continents like Europe, America and Asia Pacific. Previous conferences were held in city like USA, with success. Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting
4th African Pharma Congress
In the light of this theme, the conference series aims to provide a forum for international researchers from various areas of pharmaceutical sciences like chemical processing, industrial practice, analytical methods and pharmacological actions by providing a platform for critical analysis of new agenda, and to share latest cutting-edge research findings and results about all aspects of Pharmacy We are honoured to invite pharmacists, researchers, professors, scientific communities, delegates, students, business